Your session is about to expire
← Back to Search
Recombinant Von Willebrand Factor + Tranexamic Acid for Postpartum Hemorrhage
Study Summary
This trial is testing whether a recombinant von Willebrand factor can prevent postpartum hemorrhage in women with von Willebrand disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am willing to track my postpartum bleeding and any related treatments for 3 weeks.You have had an allergic reaction in the past to VWF or tranexamic acid.I haven't received treatments like DDAVP or blood products within the last 5 days.I am taking blood thinners or anti-inflammatory drugs, but aspirin is only for preventing preeclampsia.I have had heart issues, including a heart attack, stroke, or blood clots.I am pregnant and 18 years or older.I do not have a bleeding disorder other than von Willebrand Disease.I have a history of kidney disease.I have not had surgery in the last 8 weeks.I have von Willebrand disease with a history of bleeding.
- Group 1: rVWF plus TA
- Group 2: rVWF alone
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are joining this clinical trial?
"Yes, this is an ongoing study that was originally posted on June 4th, 2021. The most recent update to the listing was on July 5th, 2022. So far, 20 people have signed up at the 2 available locations."
Has this medication been tested in other scientific trials without being combined with other drugs?
"At this moment, 72 clinical trials that focus exclusively on rVWF are ongoing. Out of these research projects, 32 have reached Phase 3. Most of the tests for rVWF are being conducted in Kaohsiung City, Yanchao District; however, there are a total of 391 locations worldwide where these trials are taking place."
Are we still recruiting for this research project?
"This research study is still recruiting patients, as indicated by the most recent update on clinicaltrials.gov. The trial was originally posted over a year ago on June 4th, 2021."
Why is rVWF treatment given by itself and not with other drugs?
"rVWF is most commonly used in the treatment of hyperfibrinolysis, but can also be helpful for patients experiencing hemorrhagic episodes, von willebrand disease, and other bleeding disorders."
Is it dangerous to take rVWF by itself?
"rVWF has been studied in multiple Phase 3 trials, so there is a wealth of safety data. This gives rVWF a score of 3."
Share this study with friends
Copy Link
Messenger